Volitionrx (VNRX)CEO bought ~$7K

~$7K

Approx. value · 20K sh @ $0.35

2.55M

Holds after · shares reported

Traded

Nov 17, 2025

Filed

Nov 17, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 10, 2025Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 1 more item)
2. Oct 14, 2025Insider · 3 peopleInsiders: 3 purchases (~$130K)
3. Nov 7, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
4. Nov 7, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
5. Nov 7, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
6. Nov 13, 2025Company filing · Form 8-K · ResultsReported its results
7. Nov 17, 2025 · this disclosureInsiderCEO purchased ~$7K of VNRX shares in the open market

What came next

1. Dec 5, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 5, 2025, Volition Veterinary Diagnostics Development, LLC (“Volition Veterinary”), a majority-owned subsidiary of VolitionRx Limited (the “Company”), provided notice of termination of its employment agreement with Dr. Salvatore Thomas Butera, the Chief Executive Officer of Volition Veterinary, effective as of January 31, 2026 (the “Termination Date”).”
2. Jan 7, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
3. Feb 6, 2026Company filing · Form 8-K · Listing notice, Other newsReceived a notice from its stock exchange, and reported other company news“On February 6, 2026, VolitionRx Limited (the “Company”) received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported…”
4. Feb 17, 2026Company filing · Form 8-K · Unregistered sharesSold new shares without registering them

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Volitionrx

OQRO holds no insider, Congress, fund or contract record for Volitionrx dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VNRX page.

Other recent filings by Cameron John Reynolds, President and CEO

• SEC Form 4 at Volitionrx (VNRX)Oct 15, 2025
• SEC Form 4 at Volitionrx (VNRX)Sep 15, 2025
• SEC Form 4 at Volitionrx (VNRX)Aug 6, 2025
• SEC Form 4 at Volitionrx (VNRX)Jun 16, 2025
• SEC Form 4 at Volitionrx (VNRX)May 19, 2025

The full history of Cameron John Reynolds, President and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Volitionrx

• SEC Form 4Oct 15, 2025
• SEC Form 4Oct 15, 2025
• SEC Form 4Oct 15, 2025
• SEC Form 4Sep 15, 2025
• SEC Form 4Aug 6, 2025
• SEC Form 4Aug 6, 2025

Everything OQRO holds on this company is on its VNRX page.